Shopping Cart 0
Cart Subtotal
USD 0

XBiotech Inc (XBIT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750

Details

Summary

XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company provides monoclonal antibodies treatment for various diseases. It's lead product Xilonix, a therapeutic antibody being developed for the treatment of metastatic colorectal cancer. XBiotech offers clinical trial activity services, oncology, MRSA, and dermatology related solutions. The company develops a True Human technology to discover and develop targeted antibody candidates. It pipeline includes candidates, which target various therapeutic areas such as pyoderma gangrenosum, plaque psoriasis, influenza and Type II diabetes, among others. It has operations in the US, Switzerland, Japan and Germany. XBiotech is headquartered in Austin, Texas, the US.

XBiotech Inc (XBIT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

XBiotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

XBiotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

XBiotech Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

XBiotech Enters into Agreement with Cedars-Sinai Medical Center 11

Xbiotech Enters into Research Agreement with Case Western Reserve University School of Medicine 12

Xbiotech Enters into Agreement with NCIC Clinical Trials 13

Xbiotech Enters into Research Agreement with South Texas Blood & Tissue Center 14

Licensing Agreements 15

XBiotech Enters into Licensing Agreement with CT Atlantic 15

Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 16

Xbiotech Enters Into Licensing Agreement With Lonza Sales 17

XBiotech Enters Into Licensing Agreement With Strox Biopharma 18

Equity Offering 19

Xbiotech Raises USD31.8 Million in Public Offering of Shares 19

XBiotech Raises USD1 Million in Public Offering of Shares 20

XBiotech Raises USD1.8 Million in Public Offering of Shares 21

Xbiotech Raises USD76 Million in IPO 22

XBiotech Inc-Key Competitors 23

XBiotech Inc-Key Employees 24

XBiotech Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Corporate Communications 26

Sep 12, 2018: XBiotech appoints Dr. Peter Libby to its Scientific Advisory Board 26

Apr 10, 2017: XBiotech Announces Additions To Its Scientific Advisory Board 27

Product News 29

11/14/2017: XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions 29

11/03/2017: XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions 30

10/03/2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board 31

09/20/2018: XBiotech announces addition of top dermatologist and researcher Dr. Alice Gottlieb to its team 32

09/15/2017: Refusal of the marketing authorisation for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech 33

09/13/2018: XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis 34

08/27/2018: Xbiotech announces publication of breakthrough findings for potential role of interleukin-1 alpha in risk for heart attacks 35

06/08/2017: EMA Adopts a Negative Opinion for Human IgG1 mAb Specific for Human Interleukin-1 Alpha XBiotech 36

Product Approvals 37

Apr 20, 2017: XBiotech Announces Outcome of EMA's Oral Explanation Meeting 37

Clinical Trials 38

Sep 24, 2018: XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa 38

Jul 10, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa 39

May 22, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis 40

Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology 41

Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 42

Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 43

Dec 04, 2017: XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology 44

Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer 45

Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 46

Jun 09, 2017: XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis 47

Jun 01, 2017: XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting 48

May 30, 2017: Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer 49

Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application 50

Feb 21, 2017: Xbiotech Reports Affirmative Interim Analysis Of Global Phase 3 Colorectal Cancer Study 51

Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa 52

Jan 17, 2017: XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology 53

Other Significant Developments 54

Aug 10, 2018: XBiotech Highlights Quarterly Developments 54

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

XBiotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

XBiotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

XBiotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

XBiotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

XBiotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9

XBiotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

XBiotech Enters into Agreement with Cedars-Sinai Medical Center 11

Xbiotech Enters into Research Agreement with Case Western Reserve University School of Medicine 12

Xbiotech Enters into Agreement with NCIC Clinical Trials 13

Xbiotech Enters into Research Agreement with South Texas Blood & Tissue Center 14

XBiotech Enters into Licensing Agreement with CT Atlantic 15

Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 16

Xbiotech Enters Into Licensing Agreement With Lonza Sales 17

XBiotech Enters Into Licensing Agreement With Strox Biopharma 18

Xbiotech Raises USD31.8 Million in Public Offering of Shares 19

XBiotech Raises USD1 Million in Public Offering of Shares 20

XBiotech Raises USD1.8 Million in Public Offering of Shares 21

Xbiotech Raises USD76 Million in IPO 22

XBiotech Inc, Key Competitors 23

XBiotech Inc, Key Employees 24

XBiotech Inc, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

XBiotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company provides monoclonal antibodies treatment for various diseases. It's lead product Xilonix, a therapeutic antibody being developed for the treatment of metastatic colorectal cancer. XBiotech offers clinical trial activity services, oncology, MRSA, and dermatology related solutions. The company develops a True Human technology to discover and develop targeted antibody candidates. It pipeline includes candidates, which target various therapeutic areas such as pyoderma gangrenosum, plaque psoriasis, influenza and Type II diabetes, among others. It has operations in the US, Switzerland, Japan and Germany. XBiotech is headquartered in Austin, Texas, the US.

XBiotech Inc (XBIT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

XBiotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

XBiotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

XBiotech Inc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

XBiotech Enters into Agreement with Cedars-Sinai Medical Center 11

Xbiotech Enters into Research Agreement with Case Western Reserve University School of Medicine 12

Xbiotech Enters into Agreement with NCIC Clinical Trials 13

Xbiotech Enters into Research Agreement with South Texas Blood & Tissue Center 14

Licensing Agreements 15

XBiotech Enters into Licensing Agreement with CT Atlantic 15

Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 16

Xbiotech Enters Into Licensing Agreement With Lonza Sales 17

XBiotech Enters Into Licensing Agreement With Strox Biopharma 18

Equity Offering 19

Xbiotech Raises USD31.8 Million in Public Offering of Shares 19

XBiotech Raises USD1 Million in Public Offering of Shares 20

XBiotech Raises USD1.8 Million in Public Offering of Shares 21

Xbiotech Raises USD76 Million in IPO 22

XBiotech Inc-Key Competitors 23

XBiotech Inc-Key Employees 24

XBiotech Inc-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Corporate Communications 26

Sep 12, 2018: XBiotech appoints Dr. Peter Libby to its Scientific Advisory Board 26

Apr 10, 2017: XBiotech Announces Additions To Its Scientific Advisory Board 27

Product News 29

11/14/2017: XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions 29

11/03/2017: XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions 30

10/03/2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board 31

09/20/2018: XBiotech announces addition of top dermatologist and researcher Dr. Alice Gottlieb to its team 32

09/15/2017: Refusal of the marketing authorisation for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech 33

09/13/2018: XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis 34

08/27/2018: Xbiotech announces publication of breakthrough findings for potential role of interleukin-1 alpha in risk for heart attacks 35

06/08/2017: EMA Adopts a Negative Opinion for Human IgG1 mAb Specific for Human Interleukin-1 Alpha XBiotech 36

Product Approvals 37

Apr 20, 2017: XBiotech Announces Outcome of EMA's Oral Explanation Meeting 37

Clinical Trials 38

Sep 24, 2018: XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa 38

Jul 10, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa 39

May 22, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis 40

Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology 41

Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 42

Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 43

Dec 04, 2017: XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology 44

Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer 45

Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 46

Jun 09, 2017: XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis 47

Jun 01, 2017: XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting 48

May 30, 2017: Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer 49

Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application 50

Feb 21, 2017: Xbiotech Reports Affirmative Interim Analysis Of Global Phase 3 Colorectal Cancer Study 51

Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa 52

Jan 17, 2017: XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology 53

Other Significant Developments 54

Aug 10, 2018: XBiotech Highlights Quarterly Developments 54

Appendix 57

Methodology 57

About GlobalData 57

Contact Us 57

Disclaimer 57


List Of Figure

List of Figures

XBiotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

XBiotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

XBiotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

XBiotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

XBiotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9

XBiotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

XBiotech Enters into Agreement with Cedars-Sinai Medical Center 11

Xbiotech Enters into Research Agreement with Case Western Reserve University School of Medicine 12

Xbiotech Enters into Agreement with NCIC Clinical Trials 13

Xbiotech Enters into Research Agreement with South Texas Blood & Tissue Center 14

XBiotech Enters into Licensing Agreement with CT Atlantic 15

Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 16

Xbiotech Enters Into Licensing Agreement With Lonza Sales 17

XBiotech Enters Into Licensing Agreement With Strox Biopharma 18

Xbiotech Raises USD31.8 Million in Public Offering of Shares 19

XBiotech Raises USD1 Million in Public Offering of Shares 20

XBiotech Raises USD1.8 Million in Public Offering of Shares 21

Xbiotech Raises USD76 Million in IPO 22

XBiotech Inc, Key Competitors 23

XBiotech Inc, Key Employees 24

XBiotech Inc, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

XBiotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.